UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
April 17, 2017
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
Nevada |
|
001-35756 |
|
74-2897368 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
|
|
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida |
|
33913 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(239) 768-0600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
||
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective April 18, 2017, Mark Machulcz, Vice President of Operations has left NeoGenomics, Inc. (the “Company”) to pursue other opportunities. On an interim basis, our California operations will report to Robert Shovlin, the President of our Clinical Services division while our Florida, Tennessee and Texas operations will report to Dr. Steven Brodie, who has been appointed Vice President of Operations.
|
|
|
|
Item 8.01. |
Other Events. |
On April 19, 2017, Edwin F. Weidig III, was promoted to Vice President of Finance and he will also continue to serve as the Principal Accounting Officer for NeoGenomics Inc. Mr. Weidig has served as our Corporate Controller since October 2007 and as our Director of Finance and Principal Accounting Officer since January 2012.
|
|
|
|
|
|
|
|
|
|
Item 9.01. |
Financial Statements and Exhibits. |
|
|
|
|
|
|
(a) |
Not applicable |
|
|
|
|
|
|
(b) |
Not applicable |
|
|
|
|
|
|
(c) |
Not applicable |
|
|
|
|
|
|
(d) |
Not applicable |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
NEOGENOMICS, INC. |
|
|
|
|
|
By: |
|
/s/ George Cardoza |
|
|
|
George Cardoza |
|
|
|
Chief Financial Officer |
Date: April 21, 2017
3